{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T07:45:29Z","timestamp":1782719129838,"version":"3.54.5"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":58,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Research Institute for Oncology, Hematology and Cell Therapy"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Leukemic stem cells (LSCs) are the cellular reservoir most strongly implicated in relapse of acute myeloid leukemia, yet their operational detection by multiparameter flow cytometry remains challenging because of immunophenotypic overlap with normal progenitors and variability across assays. Including CD45RA in the CD34\u207aCD38\u207b gating strategy substantially improves discrimination between malignant and normal stem\/progenitor populations and thus enables more precise LSC enumeration in a single-tube format. Given the clinical importance of accurately quantifying the LSC compartment, we evaluated a refined single-tube flow cytometry assay that incorporates CD45RA within the CD34\u2009+\u2009CD38- gate to increase specificity for the leukemic stem compartment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In a retrospective cohort of 109 AML bone marrow samples, measurable residual disease (MRD) was assessed with a conventional three-tube, 8-color panel and LSCs were enumerated using an adapted single-tube, 8-color panel defining LSCs as CD34\u2009+\u2009CD38-CD45RA\u2009+\u2009. To ensure analytical reliability we applied a formal lower limit of quantification (LLOQ), defined empirically as a cluster of 50 CD45\u2009+\u2009events; samples below the sample-specific LLOQ were not called positive. Positivity thresholds were set at\u2009\u2265\u20090.1% for MRD and\u2009\u2265\u20090.004% for LSCs. Group comparisons used the Mann\u2013Whitney U test and associations were quantified by Pearson correlation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      LSCs were detectable in 28\/109 (25.7%) patients, while MRD positivity was observed in 37\/109 (33.9%) patients. A robust association was demonstrated between LSC presence and MRD positivity (p\u2009=\u20090.00035). The LSC burden was significantly elevated in MRD-positive patients, and concomitantly, MRD levels were profoundly higher in patients harboring detectable LSCs (p\u2009=\u20092.01\u2009\u00d7\u200910\u207b\u2079). A strong positive correlation was observed between LSC and MRD levels across the entire cohort (R\u2009=\u20090.66, p\u2009=\u20093.2\u2009\u00d7\u200910\u207b\n                      <jats:sup>15<\/jats:sup>\n                      ). LSC and MRD status were independent of sex, FLT3, or NPM1 mutation status. Immunophenotypic profiling of the LSC compartment revealed predominant aberrant co-expression of CD33 (89.3%) and a multi-marker cocktail (89.3%), with CD44 (67.9%) and CD123 (53.6%) also frequently observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The implementation of a refined LSC detection assay, leveraging CD45RA gating and a stringent LLOQ, yields a specific and clinically actionable quantification of the LSC reservoir in AML. The strong correlation between the CD34\u2009+\u2009CD38-CD45RA\u2009+\u2009LSC subset and MRD status suggests its potential as a complementary biomarker for residual disease monitoring; however, prospective validation in outcome-annotated cohorts is required to establish its prognostic utility and clinical applicability.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13287-026-05038-w","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T10:54:21Z","timestamp":1777719261000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Refined detection of CD34\u207aCD38\u207bCD45RA\u207a leukemic stem cells using a single-tube flow cytometry assay and its strong association with measurable residual disease in acute myeloid leukemia: a retrospective cohort study"],"prefix":"10.1186","volume":"17","author":[{"given":"Amir Abbas","family":"Navidinia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrbanoo","family":"Rostami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najibe","family":"Karami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammadreza","family":"Shemshadinia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habibeh Sabri","family":"Patekhor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akram","family":"Hajaliaskari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahereh","family":"Rostami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Barkhordar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Vaezi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghasem","family":"Janbabaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahram","family":"Chahardouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,2]]},"reference":[{"issue":"12","key":"5038_CR1","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136\u201352.","journal-title":"N Engl J Med"},{"issue":"3","key":"5038_CR2","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/ajh.26822","volume":"98","author":"S Shimony","year":"2023","unstructured":"Shimony S, Stahl M, Stone RM. Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98(3):502\u201326.","journal-title":"Am J Hematol"},{"issue":"6","key":"5038_CR3","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000572","volume":"5","author":"F Thol","year":"2021","unstructured":"Thol F, Heuser M. Treatment for relapsed\/refractory acute myeloid leukemia. Hemasphere. 2021;5(6):e572.","journal-title":"Hemasphere"},{"issue":"1","key":"5038_CR4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41375-023-02084-8","volume":"38","author":"RB Walter","year":"2024","unstructured":"Walter RB. Perspective on measurable residual disease testing in acute myeloid leukemia. Leukemia. 2024;38(1):10\u20133.","journal-title":"Leukemia"},{"issue":"26","key":"5038_CR5","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1182\/blood.2021013626","volume":"138","author":"M Heuser","year":"2021","unstructured":"Heuser M, Freeman S, Ossenkoppele G, Buccisano F, Hourigan C, Ngai L, et al. 2021 update measurable residual disease in acute myeloid leukemia: European leukemia net working party consensus document. Blood. 2021;138(26):2753\u201367.","journal-title":"Blood"},{"issue":"1","key":"5038_CR6","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41408-025-01298-6","volume":"15","author":"C Jimenez-Vicente","year":"2025","unstructured":"Jimenez-Vicente C, Cardus A, Casta\u00f1o-Diez S, Ramil G, Garcia-Avila S, Gomez-Perez L, et al. Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations. Blood Cancer J. 2025;15(1):94.","journal-title":"Blood Cancer J"},{"issue":"2","key":"5038_CR7","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3324\/haematol.2022.280800","volume":"108","author":"P Stelmach","year":"2023","unstructured":"Stelmach P, Trumpp A. Leukemic stem cells and therapy resistance in acute myeloid leukemia. Haematologica. 2023;108(2):353.","journal-title":"Haematologica"},{"key":"5038_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2025.102526","author":"B Wang","year":"2025","unstructured":"Wang B, Reville PK, Abbas HA. Therapeutic hurdles in acute myeloid leukemia: leukemic stem cells, inflammation and immune dysfunction. Curr Opin Pharmacol. 2025. https:\/\/doi.org\/10.1016\/j.coph.2025.102526.","journal-title":"Curr Opin Pharmacol"},{"issue":"9","key":"5038_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0107587","volume":"9","author":"M Terwijn","year":"2014","unstructured":"Terwijn M, Zeijlemaker W, Kelder A, Rutten AP, Snel AN, Scholten WJ, et al. Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia. PLoS ONE. 2014;9(9):e107587.","journal-title":"PLoS ONE"},{"issue":"2","key":"5038_CR10","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1172\/JCI68101","volume":"124","author":"Y Kagoya","year":"2014","unstructured":"Kagoya Y, Yoshimi A, Kataoka K, Nakagawa M, Kumano K, Arai S, et al. Positive feedback between NF-\u03baB and TNF-\u03b1 promotes leukemia-initiating cell capacity. J Clin Investig. 2014;124(2):528\u201342.","journal-title":"J Clin Investig"},{"key":"5038_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.775128","volume":"12","author":"T Marchand","year":"2021","unstructured":"Marchand T, Pinho S. Leukemic stem cells: from leukemic niche biology to treatment opportunities. Front Immunol. 2021;12:775128.","journal-title":"Front Immunol"},{"issue":"7633","key":"5038_CR12","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nature20598","volume":"540","author":"SW Ng","year":"2016","unstructured":"Ng SW, Mitchell A, Kennedy JA, Chen WC, McLeod J, Ibrahimova N, et al. A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature. 2016;540(7633):433\u20137.","journal-title":"Nature"},{"issue":"5","key":"5038_CR13","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/s41375-018-0326-3","volume":"33","author":"W Zeijlemaker","year":"2019","unstructured":"Zeijlemaker W, Grob T, Meijer R, Hanekamp D, Kelder A, Carbaat-Ham JC, et al. CD34+ CD38\u2212 leukemic stem cell frequency to predict outcome in acute myeloid leukemia. Leukemia. 2019;33(5):1102\u201312.","journal-title":"Leukemia"},{"issue":"5","key":"5038_CR14","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1182\/blood.2021014604","volume":"140","author":"S-Q Li","year":"2022","unstructured":"Li S-Q, Xu L-P, Wang Y, Zhang X-H, Chen H, Chen Y-H, et al. An LSC-based MRD assay to complement the traditional MFC method for prediction of AML relapse: a prospective study. Blood. 2022;140(5):516\u201320.","journal-title":"Blood"},{"issue":"2","key":"5038_CR15","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41375-024-02148-3","volume":"38","author":"E Klyuchnikov","year":"2024","unstructured":"Klyuchnikov E, Badbaran A, Massoud R, Freiberger P, Wolschke C, Ayuk F, et al. Peri-transplant flow-MRD assessment of cells with leukemic stem cells (LSC) associated phenotype in AML patients undergoing allogeneic stem cell transplantation in CR. Leukemia. 2024;38(2):386\u20138.","journal-title":"Leukemia"},{"key":"5038_CR16","first-page":"2657","volume":"141","author":"LL Ngai","year":"2023","unstructured":"Ngai LL, Hanekamp D, Janssen F, Carbaat-Ham J, Hofland MA, Fayed MME, et al. Prospective validation of the prognostic relevance of CD34+ CD38\u2013AML stem cell frequency in the HOVON-SAKK132 trial. Blood, The J of the American Soc of Hematology. 2023;141:2657\u201361.","journal-title":"Blood, The J of the American Soc of Hematology"},{"key":"5038_CR17","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1182\/blood-2024-205457","volume":"144","author":"A Plesa","year":"2024","unstructured":"Plesa A, Mathis S, Dumezy F, Lhoumeau A-C, Saada V, Arnoux I, et al. Flow MRD monitoring combining Laip\/Dfn and CD34+ CD38-LSCs is a strong predictor of outcome in adult AML independently of the ELN-2022 risk: first results from the Multicentric Acute Leukemia French Intergroup MRD Flow Network. Blood. 2024;144:226.","journal-title":"Blood"},{"key":"5038_CR18","doi-asserted-by":"crossref","unstructured":"Cloos J, Valk PJ, Thiede C, D\u00f6hner K, Roboz GJ, Wood BL, et al. 2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working Party. Blood. 2025.","DOI":"10.1182\/blood.2025031480"},{"issue":"10","key":"5038_CR19","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1007\/s00277-012-1501-7","volume":"91","author":"K Hwang","year":"2012","unstructured":"Hwang K, Park C-J, Jang S, Chi H-S, Kim D-Y, Lee J-H, et al. Flow cytometric quantification and immunophenotyping of leukemic stem cells in acute myeloid leukemia. Ann Hematol. 2012;91(10):1541\u20136.","journal-title":"Ann Hematol"},{"issue":"2","key":"5038_CR20","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/leu.2015.252","volume":"30","author":"W Zeijlemaker","year":"2016","unstructured":"Zeijlemaker W, Kelder A, Oussoren-Brockhoff Y, Scholten W, Snel A, Veldhuizen D, et al. A simple one-tube assay for immunophenotypical quantification of leukemic stem cells in acute myeloid leukemia. Leukemia. 2016;30(2):439\u201346.","journal-title":"Leukemia"},{"issue":"5","key":"5038_CR21","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s12185-017-2221-5","volume":"105","author":"D Hanekamp","year":"2017","unstructured":"Hanekamp D, Cloos J, Schuurhuis GJ. Leukemic stem cells: identification and clinical application. Int J Hematol. 2017;105(5):549\u201357.","journal-title":"Int J Hematol"},{"issue":"1","key":"5038_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/cpcy.66","volume":"91","author":"W Zeijlemaker","year":"2019","unstructured":"Zeijlemaker W, Kelder A, Cloos J, Schuurhuis GJ. Immunophenotypic detection of measurable residual (stem cell) disease using LAIP approach in acute myeloid leukemia. Curr Protoc Cytom. 2019;91(1):e66.","journal-title":"Curr Protoc Cytom"},{"issue":"10","key":"5038_CR23","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1002\/cyto.a.24320","volume":"99","author":"M Cheung","year":"2021","unstructured":"Cheung M, Campbell JJ, Whitby L, Thomas RJ, Braybrook J, Petzing J. Current trends in flow cytometry automated data analysis software. Cytometry A. 2021;99(10):1007\u201321.","journal-title":"Cytometry A"},{"key":"5038_CR24","first-page":"56386","volume":"133","author":"J Cloos","year":"2018","unstructured":"Cloos J, Harris JR, Janssen JJ, Kelder A, Huang F, Sijm G, et al. Comprehensive protocol to sample and process bone marrow for measuring measurable residual disease and leukemic stem cells in acute myeloid leukemia. J of vis exp: JoVE. 2018;133:56386.","journal-title":"J of vis exp: JoVE"},{"issue":"1","key":"5038_CR25","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000676","volume":"6","author":"JM Tettero","year":"2022","unstructured":"Tettero JM, Freeman S, Buecklein V, Venditti A, Maurillo L, Kern W, et al. Technical aspects of flow cytometry-based measurable residual disease quantification in acute myeloid leukemia: experience of the European LeukemiaNet MRD Working Party. Hemasphere. 2022;6(1):e676.","journal-title":"Hemasphere"},{"issue":"2","key":"5038_CR26","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/bjh.13941","volume":"173","author":"B Kersten","year":"2016","unstructured":"Kersten B, Valkering M, Wouters R, van Amerongen R, Hanekamp D, Kwidama Z, et al. CD 45 RA, a specific marker for leukaemia stem cell sub-populations in acute myeloid leukaemia. Br J Haematol. 2016;173(2):219\u201335.","journal-title":"Br J Haematol"},{"issue":"9","key":"5038_CR27","doi-asserted-by":"publisher","first-page":"e36","DOI":"10.1038\/bcj.2011.35","volume":"1","author":"D Wisniewski","year":"2011","unstructured":"Wisniewski D, Affer M, Willshire J, Clarkson B. Further phenotypic characterization of the primitive lineage\u2212 CD34+ CD38\u2212 CD90+ CD45RA\u2212 hematopoietic stem cell\/progenitor cell sub-population isolated from cord blood, mobilized peripheral blood and patients with chronic myelogenous leukemia. Blood Cancer J. 2011;1(9):e36-e.","journal-title":"Blood Cancer J"},{"issue":"1","key":"5038_CR28","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/cyto.b.22201","volume":"108","author":"T Reuvekamp","year":"2025","unstructured":"Reuvekamp T, Janssen LL, Ngai LL, Carbaat-Ham J, den Hartog D, Scholten WJ, et al. The role of the primitive marker CD133 in CD34-negative acute myeloid leukemia for the detection of leukemia stem cells. Cytometry B Clin Cytom. 2025;108(1):23\u201334.","journal-title":"Cytometry B Clin Cytom"},{"issue":"2","key":"5038_CR29","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/ijlh.14007","volume":"45","author":"S Gajendra","year":"2023","unstructured":"Gajendra S, Gupta R, Thakral D, Gupta SK, Jain G, Bakhshi S, et al. CD34 negative HLA-DR negative acute myeloid leukaemia: A higher association with NPM1 and FLT3-ITD mutations. Int J Lab Hematol. 2023;45(2):221\u20138.","journal-title":"Int J Lab Hematol"},{"issue":"5","key":"5038_CR30","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/cyto.b.21108","volume":"84","author":"B Wood","year":"2013","unstructured":"Wood B, Jevremovic D, B\u00e9n\u00e9 MC, Yan M, Jacobs P, Litwin V, et al. Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS\u2013part V\u2013assay performance criteria. Cytometry B Clin Cytom. 2013;84(5):315\u201323.","journal-title":"Cytometry B Clin Cytom"},{"key":"5038_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.867684","volume":"12","author":"AM Kamel","year":"2022","unstructured":"Kamel AM, Elsharkawy NM, Kandeel EZ, Hanafi M, Samra M, Osman RA. Leukemia stem cell frequency at diagnosis correlates with measurable\/minimal residual disease and impacts survival in adult acute myeloid leukemia. Front Oncol. 2022;12:867684.","journal-title":"Front Oncol"},{"issue":"11","key":"5038_CR32","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1038\/nbt1350","volume":"25","author":"F Ishikawa","year":"2007","unstructured":"Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, Tanaka S, et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol. 2007;25(11):1315\u201321.","journal-title":"Nat Biotechnol"},{"issue":"20","key":"5038_CR33","doi-asserted-by":"publisher","first-page":"5118","DOI":"10.1182\/bloodadvances.2020001742","volume":"4","author":"H Herrmann","year":"2020","unstructured":"Herrmann H, Sadovnik I, Eisenwort G, R\u00fclicke T, Blatt K, Herndlhofer S, et al. Delineation of target expression profiles in CD34+\/CD38\u2212 and CD34+\/CD38+ stem and progenitor cells in AML and CML. Blood Adv. 2020;4(20):5118\u201332.","journal-title":"Blood Adv"},{"issue":"12","key":"5038_CR34","doi-asserted-by":"publisher","first-page":"227","DOI":"10.4252\/wjsc.v9.i12.227","volume":"9","author":"A Plesa","year":"2017","unstructured":"Plesa A, Dumontet C, Mattei E, Tagoug I, Hayette S, Sujobert P, et al. High frequency of CD34+ CD38-\/low immature leukemia cells is correlated with unfavorable prognosis in acute myeloid leukemia. World j of stem cells. 2017;9(12):227.","journal-title":"World j of stem cells"},{"issue":"6","key":"5038_CR35","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1182\/blood.2022018071","volume":"142","author":"F Anjos-Afonso","year":"2023","unstructured":"Anjos-Afonso F, Bonnet D. Human CD34+ hematopoietic stem cell hierarchy: how far are we with its delineation at the most primitive level? Blood. 2023;142(6):509\u201318.","journal-title":"Blood"},{"issue":"8","key":"5038_CR36","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1084\/jem.20151775","volume":"213","author":"L Quek","year":"2016","unstructured":"Quek L, Otto GW, Garnett C, Lhermitte L, Karamitros D, Stoilova B, et al. Genetically distinct leukemic stem cells in human CD34\u2212 acute myeloid leukemia are arrested at a hemopoietic precursor-like stage. J Exp Med. 2016;213(8):1513\u201335.","journal-title":"J Exp Med"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-026-05038-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-026-05038-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-026-05038-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T07:01:20Z","timestamp":1782716480000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13287-026-05038-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,2]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5038"],"URL":"https:\/\/doi.org\/10.1186\/s13287-026-05038-w","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,2]]},"assertion":[{"value":"19 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol for the approved project titled \u201cRefined Detection of CD34\u207aCD38\u207bCD45RA\u207a Leukemic Stem Cells Using a Single-Tube Flow Cytometry Assay and Its Strong Association with Measurable Residual Disease in Acute Myeloid Leukemia: a retrospective cohort study\u201d was reviewed and approved by the Research Ethics Committee of the Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences (approval no. IR.TUMS.HORCSCT.REC.1403.024; approval date 12 June 2024). Two co-authors, Mohammad Vaezi (M.V.) and Ghasem Janbabaei (G.J.), are members of this committee; both were formally recused from all discussions, evaluations, and decisions regarding this protocol and did not participate in the ethical review or approval process. Independent committee members, therefore, carried out ethical review and approval in accordance with institutional procedures. Written informed consent was obtained from all participants prior to sample collection. The study was conducted in accordance with the Declaration of Helsinki and relevant national regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Two co-authors, Mohammad Vaezi (M.V.) and Ghasem Janbabaei (G.J.), are members of this committee; both were formally recused from all discussions, evaluations, and decisions regarding this protocol and did not participate in the ethical review or approval process. Independent committee members, therefore, carried out ethical review and approval in accordance with institutional procedures.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"229"}}